Prioritizing polio

Expert Review of Vaccines

Volumn 11, Issue 12, 2012, Pages 1389-1392

  Rath, Barbara ^a   Ali, Mohammad ^b   Elemuwa, Chris ^c   Maurer, Wolfgang ^d   Bouder, Frederic ^e   Mworozi, Edison ^f   Diedrich, Sabine ^g   Khamesipour, Ali ^h   Chitwood, Iga ⁱ   Kochhar, Sonali ^j  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b International Vaccine Institute   (South Korea)

^c National Primary Healthcare Department Agency (NPHCDA)   (Nigeria)

^d Medical University of Vienna   (Austria)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f MAKERERE UNIVERSITY   (Uganda)

^g ROBERT KOCH INSTITUTE   (Germany)

^h TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

ⁱ Vienna Vaccine Safety Initiative   (Germany)

^j PATH   (India)

more..

Author keywords

benefit; cost; eradication; Nigeria; poliomyelitis; prevention; vaccination

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE;

COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATOR; ERADICATION THERAPY; GOVERNMENT; HAEMOPHILUS INFECTION; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; IMMUNIZATION; INFECTION CONTROL; LIFE EXPECTANCY; MORTALITY; NIGERIA; PHYSICAL ACTIVITY; POLIOMYELITIS; POLIOMYELITIS VIRUS; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; VIRUS TRANSMISSION;

DISEASE ERADICATION; HUMANS; IMMUNIZATION PROGRAMS; NIGERIA; POLIOMYELITIS; POLIOVIRUS VACCINES; VACCINATION; WORLD HEALTH;

EID: 84871535523     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.128     Document Type: Review

References (22)

1. WHO. Ending polio, one type at a time. Bulletin of the World Health Organization 90(7), 482-483 (2012).
2. Duintjer Tebbens RJ, Pallansch MA, Cochi SL et al. Economic analysis of the global polio eradication initiative. Vaccine 29(2), 334-343 (2010).
3. Eichler HG, Kong SX, Gerth WC, Mavros P, Jönsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 7(5), 518-528 (2004).
4. Pliskin J, Shepard D, Weinstein M. Utility functions for life years and health status. Operations Research 28(1), 206-224 (1980).
5. Slovic P. Perception of risk. Science 236(4799), 280-285 (1987).
6. Rath B, Ali M, Codarini G et al. Promoting evidence-based vaccine safety research and communication-the Vienna Vaccine Safety Initiative. J. Trop. Pediatr. 58(3), 167-169 (2012).
7. Fischhoff B. Acceptable risk. Cambridge University Press, Cambridge, UK (1981).
8. Chen RT. Vaccine risks: real, perceived and unknown. Vaccine 17(Suppl. 3), S41-S46 (1999).
9. Dutta M, Basu RN. Lessons from smallpox eradication campaign in Bihar state and in India. Vaccine 29(Suppl. 4), D19-D21 (2011).
10. Dowdle WR, Cochi SL. The principles and feasibility of disease eradication. Vaccine 29(Suppl. 4), D70-D73 (2011).
11. Thompson KM, Tebbens RJ. Eradication versus control for poliomyelitis: an economic analysis. Lancet 369(9570), 1363-1371 (2007).
12. Barrett S. Eradication versus control: the economics of global infectious disease policies. Bull. World Health Organ. 82(9), 683-688 (2004).
13. Nelson AM. The cost of disease eradication. Smallpox and bovine tuberculosis. Ann. NY Acad. Sci. 894, 83-91 (1999).
14. Bouder F, Löfstedt RE, Slavin D. The tolerability of risk: a new framework for risk management. Earthscan, London, UK (2007).
15. Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save money? Health economics and the presidential candidates. N. Engl. J. Med. 358(7), 661-663 (2008).
16. Frew EJ, Bhatti M, Win K et al. Cost-effectiveness of a community-based physical activity programme for adults (Be Active) in the UK: an economic analysis within a natural experiment. Br. J. Sports Med. doi:10.1136/bjsports- 2012-091202 (2012) (Epub ahead of print).
17. Peters JL, Anderson R. The cost-effectiveness of mandatory 20 mph zones for the prevention of injuries. J. Public Health (Oxf.) doi:10.1093/pubmed/ fds067 (2012) (Epub ahead of print).
18. Parashar UD, Glass RI. Rotavirus vaccines-early success, remaining questions. N. Engl. J. Med. 360(11), 1063-1065 (2009).
19. Patel M, Shane AL, Parashar UD, Jiang B, Gentsch JR, Glass RI. Oral rotavirus vaccines: how well will they work where they are needed most? J. Infect. Dis. 200(Suppl. 1), 39-48 (2009).
20. John TJ. Oral polio vaccination of children in the tropics. II. Antibody response in relation to vaccine virus infection. Am. J. Epidemiol. 102(5), 414-421 (1975).
21. Serazin AC, Shackelton LA, Wilson C, Bhan MK. Improving the performance of enteric vaccines in the developing world. Nat. Immunol. 11(9), 769-773 (2010).
22. Zaman K, Sack DA, Yunus M et al.; Bangladeshi Rotavirus Vaccine study group. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine 27(9), 1333-1339 (2009).